SCHEMBL24330556

SCHEMBL24330556

Cc1cccc(CCC(C)C)c1-c1nc(N)nc(Cl)c1C

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NOS3 P29474 1/20 0.35
▸ NOS1 P29475 1/20 0.35
▸ NOS2 P35228 1/20 0.35
▸ HRH4 Q9H3N8 3/20 0.33
▸ SLC6A2 P23975 1/20 0.33
▸ SLC6A4 P31645 1/20 0.33
▸ SLC6A3 Q01959 1/20 0.33
▸ HSP90AA1 P07900 1/20 0.33
▸ ADORA2A P29274 4/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ JAK2 O60674 1/20 0.32
▸ TNF P01375 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ NOD1 Q9Y239 1/20 0.32
▸ ADORA1 P30542 2/20 0.31
▸ KCNA5 P22460 1/20 0.30
▸ MCHR1 Q99705 1/20 0.30
▸ DHFR P00374 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29515019 1.00 NOS3 (0.35) NOS3NOS1NOS2HRH4SLC6A2
SCHEMBL24331524 0.87 GABRA1 (0.36) HSP90AA1ADORA2ANPC1JAK2TNF
SCHEMBL29515213 0.87 GABRA1 (0.36) HSP90AA1ADORA2ANPC1JAK2TNF
SCHEMBL29515009 0.81 HSP90AA1 (0.35) HSP90AA1ADORA2ANPC1JAK2TNF
SCHEMBL24330533 0.81 HSP90AA1 (0.35) HSP90AA1ADORA2ANPC1JAK2TNF
SCHEMBL24330396 0.80 HSP90AA1 (0.42) HSP90AA1ADORA2ANPC1JAK2TNF
SCHEMBL29515320 0.80 HSP90AA1 (0.42) HSP90AA1ADORA2ANPC1JAK2TNF
SCHEMBL24330488 0.79 HSP90AA1 (0.34) HSP90AA1ADORA2ANPC1JAK2TNF
SCHEMBL29515202 0.79 HSP90AA1 (0.34) HSP90AA1ADORA2ANPC1JAK2TNF
SCHEMBL24331282 0.78 C5AR1 (0.36) JAK2HTTKCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230374038-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS (SAN DIEGO) LLC 2023-11-23 — — US disclosed
US-20230374038-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS (SAN DIEGO) LLC 2023-11-23 — — US disclosed
WO-2023196429-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-12 — — WO disclosed
WO-2022076620-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230374038-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B NOS3 4205/4885NOS1 4266/4885NOS2 4432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback